GLP-1 receptor agonists mimic a hormone called glucagon-like peptide-1 that your body produces naturally in the gut after eating
The ASMBS 2022 guidelines acknowledge that anti-obesity medications (AOMs) represent a valuable tool in the comprehensive management of post-bariatric weight regain, though evidence remains limited compared to primary obesity treatment
GLP-1 effectively reduces glycosylated hemoglobin A1c and fasting plasma glucose levels, while also promoting weight loss and decreasing systolic blood pressure, with a low incidence of hypoglycemia (18)
Unlike drugs that mimic GLP-1 and risk shutting down natural production, a probiotic approach supports the gut environment that naturally signals GLP-1 release
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al